Mednet Logo
HomeRadiation OncologyQuestion

What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?

5
8 Answers
Mednet Member
Mednet Member
Radiation Oncology · The Oregon Clinic-Radiation Oncology West

6 months ADT, 2 years ADT, 2 years ADT + abiraterone/prednisone seems reasonable depending on the circumstances. For example, early pelvic node recurrence for pT3b Gleason 4+5 would be a higher risk than a very late recurrence of pT2 Gleason 3+3.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

Agree that there is some nuance in patient and tumor features, but ultimately this is cancer that has shown it can spread at least to lymph nodes so I generally aim for 2 years and at least discuss Abiraterone. If toxicity is high then can consider cutting short

Things that push me to shorter course...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · SUNY Upstate Medical University

While data is lacking in this situation, our default is 2 years of dual ADT.

Our rationale is that dual ADT was of benefit in STAMPEDE for gross nodes (granted not detected by PSMA), and ~2 years is standard for poor-risk localized disease, due in large part to the risk of eventual spread in that po...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · University of Florida

At least 6 months, preferably 18 depending on tolerance

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Marshfield Clinic - Rice Lake

I use the gleason score of the resected cancer to determine the length of hormonal therapy. If we base our duration of hormonal ablation on the gleason score for primary treatment, why wouldn't we do the same for a nodal "recurrence", which is really untreated primary disease that was present at the...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · University of Texas at Tyler

One option may be to assess the androgen sensitivity of the recurrence by using Decipher, provided the area is amenable to biopsy. The result would offer the potential to tailor ADT to the patient.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Hôtel Dieu de Lévis - CISSS Chaudière-Appalaches

To answer Dr.@Dr. First Last's question, the Enzalutamide trend might be due to an extrapolation from the EMBARK trial for high-risk biochemical recurrence. Many argue that a PEACE-V approach with 6 months ADT and Enzalutamide (or another ARPI) intensification might be the path forward for PET-PSMA ...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Lafayette Radiation Center

Depends on the scenario, the variations above are pretty standard. STORM and Oligopelvis use 6 m ADT monotherapy with RT. That's my minimum. Titrate up from there based on the scenario with max as 2 years ADT and abi. Many guys received salvage RT and maybe ADT and remember being castrated. They won...

Register or Sign In to see full answer